Welcome to our dedicated page for Rhythm Pharmaceu SEC filings (Ticker: RYTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rhythm Pharmaceuticals, Inc. (RYTM) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing structured access to its public reporting. Rhythm is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, and its filings offer insight into the development and commercialization of IMCIVREE (setmelanotide) and related MC4R agonist programs.
Investors can review current reports on Form 8‑K in which Rhythm discusses material events such as quarterly and annual financial results, FDA and EMA regulatory milestones, equity offerings, and amendments to its certificate of incorporation. For example, the company has filed 8‑Ks describing FDA Priority Review and PDUFA goal dates for a supplemental New Drug Application for IMCIVREE in acquired hypothalamic obesity, as well as an 8‑K detailing an underwritten public offering of common stock and intended use of proceeds.
While this page focuses on current reports and other SEC documents, it also serves as a gateway to Rhythm’s periodic reports, where investors typically find detailed information on revenue from global sales of IMCIVREE, research and development expenses, selling, general and administrative expenses, cash position and funding runway. These filings also describe clinical programs in acquired and congenital hypothalamic obesity, genetically caused MC4R pathway diseases and Prader-Willi syndrome, along with investigational agents bivamelagon and RM-718.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, such as changes in operating expenses, financing transactions, or significant regulatory updates. Real-time ingestion from EDGAR helps surface new Rhythm filings quickly, and users can also monitor items that may relate to executive or director activity when Forms 3, 4 or 5 are filed. This combination of original documents and AI explanations is designed to make RYTM’s complex biopharmaceutical disclosures more accessible to a broad range of investors.
Rhythm Pharmaceuticals Chief Financial Officer Hunter C. Smith reported open-market sales of a total of 7,954 shares of common stock on February 17 and 19, 2026, at prices generally around $100 per share.
The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 28, 2025. After these sales, Smith directly holds 110,512 shares of Rhythm Pharmaceuticals common stock.
Rhythm Pharmaceuticals EVP Yann Mazabraud reported equity award activity involving restricted stock units and common stock. On February 14, 2026, he exercised or converted 10,000 restricted stock units into 10,000 shares of common stock at a price of $0.00 per share, reflecting the non-cash nature of the award.
After these transactions, he directly held 30,000 restricted stock units and 53,155 shares of common stock. Each restricted stock unit represents a right to receive one share of common stock and vests in four 25% installments on February 14, 2026, February 1, 2027, February 1, 2028, and February 1, 2029.
RA Capital Management and affiliates reported a sizable passive stake in Pharmaceuticals, Inc. They beneficially owned 6,666,837 shares of common stock, representing 9.99% of the company’s outstanding shares as of December 31, 2025, based on 66,736,056 shares outstanding on October 31, 2025.
The shares are directly held by RA Capital Healthcare Fund, L.P., which has delegated sole voting and investment power to RA Capital Management, L.P. Individuals Peter Kolchinsky and Rajeev Shah may be deemed beneficial owners through their control of RA Capital, but all reporting persons disclaim beneficial ownership beyond Section 13(d) requirements.
The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer, indicating a passive investment intent rather than an activist position.
Shulman Joseph, Chief Technical Officer of Pharmaceuticals, Inc., reported new equity awards. On February 11, 2026, he received 15,000 restricted stock units and stock options for 22,500 shares with a $98.47 exercise price, all held directly.
The restricted stock units vest in four equal 25% installments on February 1 of 2027, 2028, 2029 and 2030 and have no expiration date. The options were granted on February 11, 2026 and vest in 16 substantially equal installments, each after three full months of continued service, until fully exercisable by February 10, 2036.
RYTM Pharmaceuticals’ President and CEO David P. Meeker reported equity awards consisting of restricted stock units and stock options. On February 11, 2026, he received 71,900 restricted stock units, each representing the right to receive one share of common stock. These units vest 25% each on February 1, 2027, 2028, 2029 and 2030.
On the same date, he was also granted 107,850 stock options with an exercise price of $98.47 per share. These options vest in 16 substantially equal quarterly installments, based on completing each three full months of successive service after the grant date. Both awards are held directly.
Mazabraud Yann reported acquisition or exercise transactions in this Form 4 filing.
Pharmaceuticals, Inc. executive Yann Mazabraud, EVP and Head of International, reported receiving a grant of 23,350 restricted stock units on February 11, 2026. This was an award of derivative securities at a reported price of $0 per unit, held as direct ownership.
The restricted stock units give a contingent right to receive one share of common stock for each unit. They vest in four equal installments of 25% of the total grant on March 1, 2027, February 1, 2028, February 1, 2029, and February 1, 2030, and have no expiration date.
Rhythm Pharmaceuticals executive Jennifer Kayden Lee received new equity awards tied to her role as EVP, Head of North America. On February 11, 2026, she was granted 21,650 restricted stock units, each representing one share of common stock, and 32,500 stock options with a $98.47 exercise price.
The restricted stock units vest in four equal 25% installments on February 1, 2027, 2028, 2029, and 2030 and have no expiration date. The stock options expire on February 10, 2036 and vest in 16 substantially equal installments, each after three full months of continued service following the grant date. All awards are held directly.
German Christopher Paul reported acquisition or exercise transactions in a Form 4 filing for RYTM. The filing lists transactions totaling 5,215 shares. Following the reported transactions, holdings were 5,215 shares.
Rhythm Pharmaceuticals’ Chief Scientific Officer Alastair Garfield received new equity awards. On February 11, 2026, he was granted 16,650 restricted stock units, each representing one share of common stock, and 25,000 stock options with an exercise price of $98.47 per share.
The restricted stock units vest in four equal 25% installments on February 1, 2027, 2028, 2029 and 2030. The options expire on February 10, 2036 and vest in 16 substantially equal installments, each after three full months of continued service following the grant date.
Rhythm Pharmaceuticals’ Chief Human Resources Officer Pamela J. Cramer received new equity awards. On February 11, 2026, she was granted 11,650 restricted stock units, each representing one share of common stock. These RSUs vest in four equal 25% installments on February 1 of 2027, 2028, 2029, and 2030.
She was also granted stock options for 17,500 shares of common stock at an exercise price of $98.47 per share. These options vest in 16 substantially equal installments, based on completing each three full months of successive service after the grant date. All awards are held directly.